Efficacy and safety of ruxolitinib in intermediate ‐1 IPSS risk myelofibrosis patients: Results from an independent study

Hematological Oncology,Volume 36, Issue 1, Page 285-290, February 2018.
Source: Hematological Oncology - Category: Hematology Source Type: research